Sempre

Sempre Health applies behavior-based, dynamic pricing to prescription medications. Patients who are eligible through their health plan or a participating pharmaceutical brand enroll via SMS, receive a discount ID and text reminders that state the copay they should expect, and pay progressively lower out-of-pocket amounts as they refill consistently and on time. Enrollment requires no app download or password, and discounts are usable at retail pharmacies nationwide.

The company positions itself as an alternative to traditional coupons and cash-card programs by adjusting a patient's out-of-pocket cost at the point of fill or dispense according to individual adherence and benefit design. It operates a two-sided network: pharmaceutical manufacturers fund the discounts, while health plans select formulary-aligned brands, supply lists of eligible members and retain control of patient messaging. Sempre runs white-labeled member communications (print, email and SMS), enrollment and support, and provides plans a real-time dashboard covering enrollment, engagement, behavior and outcomes. Its stated therapeutic focus areas include diabetes, cardiovascular and respiratory conditions, and it has extended the platform to generics to cover a member's full chronic disease regimen.

Founding story

Sempre Health was co-founded by Anurati Mathur (CEO) and Swaraj Banerjee (CTO), who lead a team of healthcare specialists, engineers and regulatory advisors.

Business model

Sempre contracts with pharmaceutical manufacturers, which fund the point-of-sale discounts, and separately contracts with payers, to whom the adherence intervention is offered at no charge. Plans choose the brands they want covered and share eligible member lists; Sempre operates the enrollment, outreach, member support and analytics layer.

The company states that pharmaceutical manufacturers fund the member discounts and that the program is provided to health plans free of charge.

Traction

The company reports thousands of members and cites program results including a typical 15–25% increase in proportion of days covered, 45–65% out-of-pocket savings for enrolled members over 12 months, an NPS above 95, expected ROI of 3.7x and expected enrollment of 25–40% of eligible populations. In one manufacturer program, more than one in three invited patients enrolled and, over two years, enrolled diabetes patients saved roughly $300 per year and filled on time 94% of the time. Named plan relationships include UPMC and Alluma, alongside unnamed regional Blues plans.

Latest developments

Sempre announced $20M in additional funding from Cencora Ventures and Echo Health Ventures with participation from existing investors, earmarked for growing its two-sided network of manufacturers and health plans, launching products for new populations and expanding patient reach. The company also announced a generics expansion covering a member's full chronic disease regimen and an award from Modern Healthcare related to medication affordability.